Shares of BTG plc (LON:BTG) have earned a consensus rating of “Buy” from the nine analysts that are presently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is GBX 762 ($9.64).

Several research firms recently commented on BTG. Jefferies Group LLC restated a “buy” rating and issued a GBX 775 ($9.80) price target on shares of BTG plc in a research note on Tuesday, May 16th. Peel Hunt restated a “hold” rating and issued a GBX 630 ($7.97) price target on shares of BTG plc in a research note on Tuesday, May 16th. Numis Securities Ltd restated a “buy” rating and issued a GBX 900 ($11.39) price target on shares of BTG plc in a research note on Monday, May 22nd. Panmure Gordon upped their price target on shares of BTG plc from GBX 737 ($9.32) to GBX 809 ($10.23) and gave the company a “buy” rating in a research note on Tuesday, May 16th. Finally, J P Morgan Chase & Co restated a “neutral” rating and issued a GBX 790 ($9.99) price target on shares of BTG plc in a research note on Tuesday, March 28th.

Shares of BTG plc (LON BTG) opened at 668.00 on Monday. BTG plc has a 12 month low of GBX 528.36 and a 12 month high of GBX 739.50. The stock’s 50 day moving average is GBX 675.57 and its 200 day moving average is GBX 604.95. The firm’s market capitalization is GBX 2.57 billion.

In other BTG plc news, insider Rolf Soderstrom sold 22,624 shares of the stock in a transaction dated Friday, June 9th. The shares were sold at an average price of GBX 649 ($8.21), for a total transaction of £146,829.76 ($185,742.90).

WARNING: This piece of content was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/06/19/btg-plc-btg-receives-average-recommendation-of-buy-from-analysts.html.

BTG plc Company Profile

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.

Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with MarketBeat.com's FREE daily email newsletter.